Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

ns with several other parties regarding similar collaborations are ongoing. If successful, these collaborations could lead to these parties taking a licence to Silence delivery technologies.

Potential News Flow Events 2012-2014

In the near and medium term, the Directors believe there is the possibility of multiple potential news flow events from the existing product portfolio of programme deals, and opportunities within the RNAi technology platform, that could, dependent on success, act as value creation points for the business. The indicative dates are the Company's estimates, however no assurance can be given that the various events will be achieved by those dates, or indeed at all.

Internal Product Portfolio

Atu027 (treatment of solid tumours)

  • Completion of Phase I trial of Atu027 (July 2012)
  • Final Phase I results of Atu027 (third quarter of 2012)
  • Initiation of Phase Ib trial (end of 2012/early 2013)
  • Completion of Phase Ib trial (2014)

Atu111 (treatment of acute lung injury)

  • Completion of further proof-of-concept pre-clinical models (end 2012)

Partnered Product Portfolio

PF-'655 (diabetic macular oedema, glaucoma and age-related macular degeneration)

  • Completion of Phase IIb MATISSE study (2014)
  • Initiation of Phase IIa trial in glaucoma (trial start date not yet disclosed by Quark)

QPI-1002 (acute kidney injury 'AKI' and prevention of delayed graft function 'DGF')

  • Completion of Phase II trial in prevention of delayed graft function (second half of 2012)
  • Potential milestone payment upon Novartis' exercise of a license (2013)

Related Party Transaction

As part of the Fundraising, the Directors propose to issue 200,000,000 Subscription
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... TRIANGLE PARK, N.C., Nov. 17, 2010 Chimerix, Inc., ... an update to the World Health Organization (WHO) on ... at the 12th Meeting of the WHO Advisory Committee ... of CMX001 for Smallpox and Other dsDNA Viruses."  CMX001 ...
... AVANIR Pharmaceuticals, Inc. (Nasdaq: ... sell shares of its common stock in an underwritten public ... manager in the offering and Canaccord Genuity Inc., Wedbush PacGrow ... acting as co-managers for the offering.  In addition Trout Capital ...
... 2010 Imagenetix, Inc. (OTC Bulletin Board: IAGX ... ended September 30, 2010. Net sales increased 69% for the ... for the same period of last year.  Net income for ... net income of $553,000, $.05 per share, for the same ...
Cached Biology Technology:Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 2Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 3AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Imagenetix, Inc. Reports Second Quarter 2011 Results 2Imagenetix, Inc. Reports Second Quarter 2011 Results 3
(Date:4/20/2014)... with Down syndrome have a heightened risk of developing ... able to explain why. Now, a team of ... the two conditions. , In a study posted online ... researchers track the genetic chain of events that links ... havoc that occurs in ALL. Their findings are ...
(Date:4/18/2014)... For the past 20 years, researchers have published ... research findings have suggested that soil organic carbon can ... tillage systems to no-till systems. However, there is a ... in corn and soybean rotations without cover crops, small ... carbon stocks at the published rates. , "Some studies ...
(Date:4/17/2014)... In the most densely forested and most densely populated ... of human needs, values and practices. Disturbances associated with ... agriculture and development, have set the stage for management ... study reports. , The report Five anthropogenic factors ... in the Northern United States was published ...
Breaking Biology News(10 mins):Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... massive changes to the Earth's landscape , The ice ages ... happening below the ice in the oceans? , Research by ... destruction as whole communities of animals were wiped out by ... it has been thought that these ecosystems somehow dodged extinction ...
... at the Naval Research Laboratory's Marine Meteorology Division ... Monterey Bay Aquarium Research Institute and the National ... of a phenomenon known as the "milky sea." ... ship-based account. This research was published in the ...
... Wright Brothers' first biplanes to monoplanes was an inadvertent ... say two dino flight experts. , According to ... a small early Chinese dinosaur called Microraptor gui used ... to tree in the early Cretaceous. Among the evidence ...
Cached Biology News:Seafloor creatures destroyed by ice action during ice ages 2NRL scientists detect 'milky sea' phenomena 2NRL scientists detect 'milky sea' phenomena 3Wright bros. upstaged! Dinos invented biplanes 2Wright bros. upstaged! Dinos invented biplanes 3
Request Info...
... the membrane-permeant ester forms (CCF2-AM and ... beta-lactamase substrates, CCF2 and CCF4. These ... where cleavage by endogeneous cytoplasmic esterases ... charged forms, thereby trapping them in ...
Chlorine-36, 3.7 MBq, 100 uCi. 0.1-0.3 HCl.< 111 MBq/g Cl, < 3 mCi/g Cl.Dispensed to order. Please inquire for alternative pack sizes. Category: Radiochemicals &Radiation Safety, Radiochemicals....
Src cDNA Expression Kit (wild type)...
Biology Products: